CONTE, PIERFRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.635
AS - Asia 3.419
EU - Europa 3.186
OC - Oceania 19
SA - Sud America 16
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 39.283
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.570
CN - Cina 1.507
SG - Singapore 1.236
FI - Finlandia 770
IT - Italia 651
SE - Svezia 610
VN - Vietnam 470
FR - Francia 407
GB - Regno Unito 255
DE - Germania 245
IN - India 101
HK - Hong Kong 60
CA - Canada 58
RU - Federazione Russa 57
IE - Irlanda 46
UA - Ucraina 41
NL - Olanda 26
GR - Grecia 14
AU - Australia 11
BE - Belgio 11
BR - Brasile 11
ES - Italia 10
JP - Giappone 9
TR - Turchia 9
NZ - Nuova Zelanda 8
CH - Svizzera 7
CZ - Repubblica Ceca 6
KR - Corea 6
MX - Messico 6
SI - Slovenia 5
BG - Bulgaria 4
TW - Taiwan 4
AT - Austria 3
CL - Cile 3
EU - Europa 3
LT - Lituania 3
OM - Oman 3
PH - Filippine 3
PL - Polonia 3
AL - Albania 2
EG - Egitto 2
ID - Indonesia 2
IR - Iran 2
NO - Norvegia 2
PT - Portogallo 2
RO - Romania 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BZ - Belize 1
CO - Colombia 1
DK - Danimarca 1
EC - Ecuador 1
HR - Croazia 1
KZ - Kazakistan 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
PK - Pakistan 1
RS - Serbia 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 39.283
Salva come PNG Salva come JPEG
Città #
Fairfield 5.879
Woodbridge 4.007
Houston 3.240
Ann Arbor 2.755
Ashburn 2.353
Cambridge 2.043
Seattle 2.030
Wilmington 1.893
Chandler 1.857
Singapore 956
Boardman 861
San Diego 588
Princeton 579
Medford 577
Dong Ket 468
Des Moines 462
Nanjing 344
Helsinki 327
Santa Clara 281
Padova 245
Beijing 237
Roxbury 167
Shenyang 108
Hebei 100
Nanchang 90
Jiaxing 84
New York 82
Guangzhou 73
London 70
Tianjin 57
Changsha 56
Munich 56
Pune 55
Dublin 46
Hong Kong 45
Jinan 39
Columbus 37
Milan 37
Kharkiv 34
Ogden 33
Kilburn 29
Norwalk 28
Ottawa 24
Dallas 22
Falls Church 20
Rome 16
Shanghai 16
Borås 15
Hounslow 13
Ningbo 13
Venice 13
Washington 13
Los Angeles 12
Rockville 12
Haikou 11
Jacksonville 11
Selvazzano Dentro 11
Zhengzhou 11
Bologna 10
Chiswick 10
Lappeenranta 10
Redwood City 10
Brussels 9
New Bedfont 9
Hangzhou 8
Islington 8
North York 8
Rubano 8
Tappahannock 8
Chicago 7
Frankfurt am Main 7
Hefei 7
Paris 7
Piove Di Sacco 7
Prescot 7
Stockholm 7
São Paulo 7
Taizhou 7
Vicenza 7
Kunming 6
Mexico City 6
Modena 6
Montreal 6
Naples 6
Olomouc 6
Pignone 6
Southwark 6
Taiyuan 6
Toronto 6
Trieste 6
Avezzano 5
Berlin 5
Lanzhou 5
Moscow 5
Orange 5
Verona 5
Amsterdam 4
Codogno 4
Enterprise 4
Florence 4
Totale 33.821
Salva come PNG Salva come JPEG
Nome #
0.1 grams of sub-cutaneous adipose tissue (SCAT) as source of adult multipotent mesenchymal stromal cells (MSC) for cell-based therapies. 300
211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis 186
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 185
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 178
28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS) 173
A triple rare E709K and L833V/H835L EGFR mutation responsive to an irreversible pan-HER inhibitor: A case report of lung adenocarcinoma treated with afatinib 161
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 156
166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series 154
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 151
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 149
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 146
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 141
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 140
Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman 138
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer 137
Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer 136
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 134
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intra-tumor heterogeneity over time 133
In response to Jackson letter to the editor regarding safety of intravenous and oral bisphosphonates and compliance with dosing regimens 131
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 130
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 129
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 129
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? 128
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab 126
Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature 126
Immune characterization of breast cancer metastases: Prognostic implications 125
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 124
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer 123
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 122
Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature 121
A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology 120
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 118
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE 118
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 118
LKB1 and tumor metabolism: The interplay of immune and angiogenic microenvironment in lung cancer 118
Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment 117
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 117
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists 116
Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review 115
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 115
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 114
77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC) 113
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 112
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials 112
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 109
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation 107
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. 106
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 105
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 104
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry 103
Olaparib for the treatment of breast cancer 103
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities 102
Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? 102
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 102
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 102
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 102
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study 101
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 101
Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy 101
Fat grafting for breast cancer patients: From basic science to clinical studies 100
Combination chemotherapy for metastatic brain tumors. 98
Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. 98
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 98
Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model 98
Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety 97
Body mass index and prognosis of metastatic breast cancer patients receiving first line chemotherapy 97
Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer 97
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 96
LKB1 expression correlates with increased survival in advanced non-small cell lung cancer patients treated with chemotherapy and bevacizumab 96
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study 95
A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. 95
A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer 95
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 95
Ineffectiveness of 5-fluorouracil and cis-platin as second-line chemotherapy in head and neck cancer. 94
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 94
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study. 94
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 94
Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study 94
All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international phase II trial 93
Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies 93
A Catalyst for Change: The European Cancer Patient's Bill of Rights 93
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support 93
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 93
Achievements and unmet needs in the management of advanced ovarian cancer 92
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: Correlation with pathological and clinical data 92
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 91
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study. 91
Estrogen induced expansion of the growth fraction in receptor negative human breast cancer. 90
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. 90
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 90
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 90
Ribociclib as first-line therapy for HR-positive, advanced breast cancer 90
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 90
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer 90
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer 89
Effects of primary chemotherapy on biological parameters of locally advanced breast cancer. 89
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 89
Effects of sulfonylureas on tumor growth: A review of the literature 89
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 89
Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. 89
Totale 11.405
Salva come PNG Salva come JPEG
Categoria #
all - tutte 149.251
article - articoli 145.375
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 412
patent - brevetti 364
selected - selezionate 0
volume - volumi 2.085
Totale 297.487
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.825 0 0 0 0 0 0 767 880 993 565 395 225
2020/20215.089 235 291 185 292 264 539 356 448 614 466 575 824
2021/20227.508 257 976 991 545 440 388 523 716 325 223 622 1.502
2022/20234.407 1.030 290 115 484 796 485 24 275 575 56 204 73
2023/20242.115 142 277 220 144 138 242 120 102 75 69 298 288
2024/20253.092 40 684 533 269 1.316 235 15 0 0 0 0 0
Totale 39.674